The Turnbull Government will help improve the lives of those living with diabetes and hepatitis C by making two treatments more affordable, helping patients save thousands of dollars a year.
More than 170,000 Australians who face the many challenges and risks of living with hepatitis C are expected to benefit from the listing of Maviret on the Pharmaceutical Benefits Scheme (PBS).
Maviret works by stopping hepatitis C virus from multiplying and infecting new cells. It belongs to a class of new treatments which provide a cure for well over 90 percent of people treated. Without this listing, patients could pay over $50,000 per course of treatment for this medicine.
The Turnbull Government will also provide $1 million to Hepatitis Australia to continue education and awareness activities to improve hepatitis C testing and treatment uptake.
It is critically important to diagnose and treat hepatitis C early to avoid the risk of serious liver disease, including liver failure, cirrhosis and liver cancer.
Over 118,000 Australians adults living with both type 1 and 2 diabetes will be able to more easily regulate their blood sugar levels with the listing of Ryzodeg on the PBS.
Ryzodeg is the first diabetes pen to contain two types of insulin, combining a long blood sugar lowering effect insulin and a rapid acting insulin. Patients would normally pay around $930 per year for Ryzodeg.
These two new listing on the PBS will now mean that from August 1 patients will pay a maximum of $39.50 per script for these medications or just $6.40 per script for concessional patients, including pensioners.
Since coming into Government, the Coalition has helped improve the health of Australians by subsidising more than $9 billion worth of new medicines.
In the Budget we announced our commitment to invest $2.4 billion on new medicines to build on our commitment to guarantee those essential services that all Australians rely on.
Our commitment to the PBS is rock solid. Together with Medicare, it is a foundation of our world-class health care system.